SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

Launched by SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS · Apr 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how SPECT imaging can help doctors understand how certain cancer treatments work in the body, particularly for patients with advanced prostate cancer and other advanced cancers. The main goal is to see if the information gathered from these images can predict how well the treatments will work. The trial will involve 80 patients who will receive standard treatments with specialized radioactive drugs (like Radium-223 or 177Lu-DOTATATE) and will have SPECT/CT imaging done three times during their treatment. Importantly, no new medications will be given as part of this study; it is just focused on imaging and observation.

To be eligible for this trial, patients must be over 18 years old and have a confirmed diagnosis of cancer. Specific groups of patients are being targeted: those with advanced prostate cancer who are planning to receive Radium-223 and those with other advanced cancers undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617. Participants can expect to undergo a few imaging sessions that will help researchers gather important information about their treatment response. If someone is already involved in another study that conflicts with this one or cannot handle the imaging process, they may not be able to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Cohort A: Patients with advanced prostate cancer planning to undergo treatment with Radium-223
• • Cohort B: Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617
• • \*\*Eligible patients may be planning to undergo these treatments as part of standard of care or as part of another research protocol
• • Age \> 18 years
• • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• • Histologic confirmation of malignancy
• Exclusion Criteria:
• • Patient is participating in another research protocol that does not allow participation in this imaging protocol or that has schedule of procedures that would not be compatible with this protocol.
• • Patient unable to tolerate SPECT scan time, scan frequency, or position.